Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
In this study, we combine Nab-PTX, S-1 and sintilimab as adjuvant regimen to patients with
stage IIIC GC. We are aiming to investigate the recommended dose of this regimen in a phase I
study and estimate the toxicity and efficacy of this regimen in a phase II study.